Rationale and design of the TRUSTY study: A randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy

Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, Takako Eguchi-Nakajima, Hiroya Taniguchi, Satoshi Morita, Naruhito Takenaka, Daisuke Ozawa, Kuniaki Shirao

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Fingerprint Dive into the research topics of 'Rationale and design of the TRUSTY study: A randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences